Market Overview:
The global Tysabri (natalizumab) drug market is expected to register a CAGR of 7.5% during the forecast period, 2018-2030. The growth in the market can be attributed to factors such as increasing prevalence of multiple sclerosis and Crohn's disease, rising demand for better treatment options, and growing awareness about Tysabri (natalizumab) drug. However, the high cost of therapy is likely to restrain the growth of this market during the forecast period. Based on type, the global Tysabri (natalizumab) drug market has been segmented into multiple sclerosis and Crohn's disease. The multiple sclerosis segment is expected to account for a larger share of this market during the forecast period. This can be attributed to increasing prevalence of multiple sclerosis across the globe. Based on application, this market has been segmented into hospital and drugs stores segments. The hospital segment is expected to account for a larger share of this market duringthe forecast period owingto rising demand for better treatment optionsfor patients suffering from various diseases such asmultiple sclerosisandCrohn's disease .Geographically, North America dominatesthismarket followed by Europeand Asia Pacific .
 Drug Industry Outlook.svg)
Product Definition:
Tysabri (natalizumab) is an intravenous drug used to treat relapsing forms of multiple sclerosis. It is a monoclonal antibody that binds to the adhesion molecule VLA-4, preventing white blood cells from entering the central nervous system and causing inflammation.
Multiple Sclerosis:
Multiple sclerosis is a chronic disease of the central nervous system (CNS) that affects all the parts of the brain, kidneys, and nerves. The most common symptoms include visual hallucinations, double vision, stiff muscles, and problems with walking. As per multiple sclerosis Foundation 2015 statistics; around 2-3 people in 100000 are diagnosed with multiple sclerosis every year in U.S., making it one of the most common causes of CNS disorders after Parkinson's disease.
Crohn's Disease:
Crohn's disease is a type of Inflammatory Bowel Disease (IBD) that causes inflammation and pain in the digestive tract. The exact cause of Crohn's disease is unknown, but it may be triggered by environmental factors such as changes in diet, stress, and infection. Some people with Crohn's disease also have a genetic mutation that codes for the production of less than normal amounts of certain proteins required to keep the intestinal cells healthy.
Application Insights:
On the basis of application, the global tysabri (natalizumab) drug market is segmented into hospital and non-hospital settings. Hospital was estimated as the largest revenue generating segment in 2017 owing to increasing prevalence of diseases such as multiple sclerosis and Crohn¢â‚¬â„¢s disease. In addition, high treatment costs coupled with rising number of patients are expected to drive demand for expensive drugs such as tysabri (natalizumab).
The non-hospital setting is projected to be fastest growing application over the forecast period due to increasing awareness about availability of treatments other than bed rest which encourages self care activities including showering, dressing and moving around despite being hospitalized. Rising geriatric population prone to conditions like arthritis is also anticipated fuel demand for anti-inflammatory & painkilling drugs in near future.
Regional Analysis:
North America dominated the global tysabri market in terms of revenue with a share of over 60.0% in 2017. This is attributed to the higher incidence rate of multiple sclerosis and increasing awareness about this disease, high healthcare expenditure, and availability of treatment options for patients suffering from autoimmune diseases. The U.S., which accounted for a major share in North America region, has one of the highest incidences rates due to greater exposure to infectious agents that trigger autoimmune disorders such as MS (multiple sclerosis).
Growth Factors:
- Increasing incidence of multiple sclerosis (MS)
- Growing demand for better treatment options for MS
- Rising awareness about Tysabri (natalizumab) and its benefits
- Availability of favorable reimbursement policies for Tysabri (natalizumab) therapy
- Launch of new products in the same therapeutic area
Scope Of The Report
Report Attributes
Report Details
Report Title
Tysabri (natalizumab) Drug Market Research Report
By Type
Multiple Sclerosis, Crohn's Disease
By Application
Hospital, Drugs Stores
By Companies
Biogen, Biogen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
203
Number of Tables & Figures
143
Customization Available
Yes, the report can be customized as per your need.
Global Tysabri (natalizumab) Drug Market Report Segments:
The global Tysabri (natalizumab) Drug market is segmented on the basis of:
Types
Multiple Sclerosis, Crohn's Disease
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Drugs Stores
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biogen
- Biogen
 Drug Market Overview.svg)
Highlights of The Tysabri (natalizumab) Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Multiple Sclerosis
- Crohn's Disease
- By Application:
- Hospital
- Drugs Stores
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tysabri (natalizumab) Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Drug Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Tysabri is a drug used to treat rheumatoid arthritis. It works by blocking the activity of certain proteins in the body that are responsible for inflammation.
Some of the key players operating in the tysabri (natalizumab) drug market are Biogen, Biogen.
The tysabri (natalizumab) drug market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Tysabri (natalizumab) Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Tysabri (natalizumab) Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Tysabri (natalizumab) Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Tysabri (natalizumab) Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Tysabri (natalizumab) Drug Market Size & Forecast, 2020-2028
4.5.1 Tysabri (natalizumab) Drug Market Size and Y-o-Y Growth
4.5.2 Tysabri (natalizumab) Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Multiple Sclerosis
5.2.2 Crohn's Disease
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Drugs Stores
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Tysabri (natalizumab) Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Tysabri (natalizumab) Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Multiple Sclerosis
9.6.2 Crohn's Disease
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Drugs Stores
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Multiple Sclerosis
10.6.2 Crohn's Disease
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Drugs Stores
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Multiple Sclerosis
11.6.2 Crohn's Disease
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Drugs Stores
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Multiple Sclerosis
12.6.2 Crohn's Disease
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Drugs Stores
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Multiple Sclerosis
13.6.2 Crohn's Disease
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Drugs Stores
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Tysabri (natalizumab) Drug Market: Competitive Dashboard
14.2 Global Tysabri (natalizumab) Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Biogen
14.3.2 Biogen
